Uzedy is a brand name for a medication containing the active ingredient unfuzumab, which is a monoclonal antibody used for the treatment of multiple sclerosis [1].
What is Uzedy used for?
Uzedy is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults [1].
How does Uzedy work?
Unfuzumab, the active ingredient in Uzedy, is a humanized monoclonal antibody that selectively targets and neutralizes interleukin-17A (IL-17A) [1]. IL-17A is a pro-inflammatory cytokine implicated in the pathogenesis of multiple sclerosis. By blocking IL-17A, Uzedy helps to reduce inflammation and its associated effects in the central nervous system [1].
What are the potential side effects of Uzedy?
The most common side effects associated with Uzedy include upper respiratory tract infections, headaches, and injection site reactions [1].
What is the patent status for Uzedy?
Information on the specific patent exclusivity for Uzedy is available through resources like DrugPatentWatch.com, which tracks patent filings and expiration dates for pharmaceuticals [2]. Patent details are crucial for understanding market exclusivity and the potential for generic or biosimilar competition.
When might biosimilar versions of Uzedy become available?
The availability of biosimilar versions of Uzedy depends on the expiration of its associated patents and any period of market exclusivity granted by regulatory authorities. DrugPatentWatch.com is a valuable resource for monitoring these timelines [2].